Serum levels of interleukin-10 in both responders and non-responders to Direct-acting antivirals therapy for the hepatitis C virus

Association of Serum Interlukin-6 and Transforming Growth Factor Beta with Response to Antiviral Therapy for Chronic Hepatitis C Patients

The relation between interleukin 28B gene polymorphisms (rs8099917 and rs12980275) and the response of treatment of Hepatitis C Virus genotype 4 patients to Sofosbuvir and Daclat

Interleukin 10 and 12 polymorphisms and their association with treatment outcome of patients with chronic hepatitis C infection

Study of Interleukin-18 in Chronic hepatitis C virus related liver diseases

Interleukin 17 levels used as diagnostic marker for following up hepatitis C virus treatment

MOLECULAR MARKERS PREDICTING THE EFFICACY OF INTERFERON-BASED THERAPIES IN PATIENTS WITH CHRONIC HEPATITIS C

ROLE OF SERUM INTERLEUKIN – 10 AND INTERLEUKIN -28B GENE POLYMORPHISMS IN PREDICTING TREATMENT RESPONSE OF HEPATITIS C PATIENTS

Innovative Diagnostic Model Based on Beta-Catenin, Tumor Necrosis Factor-Alpha, Interleukin 21 and CA19.9 Biomarkers for Follow-up of HCC Development After DAA Therapy for HCV In

Assessing TGF β1 Gene Expression as a Prognostic Marker for Hepatocellular Carcinoma Development in HCV patients receiving Direct-Acting Antiviral (DAAs) Therapy